Calculate the cost of equity using the Security Market Line and Dividend Discount Model (DDM), the cost of debt, the market value weights, and the WACC to use your answer from the Security Market Line in your calculation for the cost of equity.

Transcribed Image Text:

Phillips Pharmaceuticals Limited (PPL) shares are publicly traded on the Toronto Stock Exchange. The common shares currently trade at a market price of $30.00 per share. PPL recently paid a dividend on its common stock of $1.50 per share. The company maintains a 60% payout policy and has a Return on Equity (ROE) of 10%. The company beta is 0.9. PPL also has long-term bonds trading on public markets. The bonds are currently trading at a quoted price of 96.54. These 5.75% semi-annual bonds have ten years left until they mature. PPL is considering a project that will expand its production facilities. The project is expected to produce annual cash flows before tax of $100,000 for the next eight years. The project is considered to be of similar risk to the risk of the firm itself. It will cost PPL $400,000 this year to get this project up and running. The assets will have no value in 8 years' time. Shuting Tia, PPL's manager of finance, has collected current data from the firm's underwriters. Government of Canada 91-day Treasury bills are currently yielding 4.25%. The The expected return on the S&P/TSX Composite Index: forecast to be 10% in the next year New equity capital could be raised by the firm at the current market price, with flotation panta costs of 4.75% of the value of the issue. 37 New bonds could be sold, with flotation costs of 3.67%. The firm faces a corporate tax rate of 40%. The assets belong in an asset class with a CCA rate of 30%. The company will seek to maintain the current capital structure based on existing market value weights. Assume flotation costs are expensed at time = 0. The firm's most recent financial statements are found below: Assets Cash Accounts Receivable. Inventories Total Current Assets Gross Fixed Assets. Accumulated Depreciation Net Fixed Assets TOTAL ASSETS Phillips Pharmaceuticals Limited. Balance Sheet As at December 31, 20XX Liabilities Accruals Accounts Payable 100,000 220,000 450,000 770,000 4,000,000 1,500,000 2,500,000 3,270,000 Total Current Liabilities. Bonds 5.75% Common stock (100,000 outstanding) Retained earnings 30,000 312,000 342.000 1,000,000 1,000,000 928,000 TOTAL LIABILITIES & OWNERS EQUITY 3,270,000 Phillips Pharmaceuticals Limited (PPL) shares are publicly traded on the Toronto Stock Exchange. The common shares currently trade at a market price of $30.00 per share. PPL recently paid a dividend on its common stock of $1.50 per share. The company maintains a 60% payout policy and has a Return on Equity (ROE) of 10%. The company beta is 0.9. PPL also has long-term bonds trading on public markets. The bonds are currently trading at a quoted price of 96.54. These 5.75% semi-annual bonds have ten years left until they mature. PPL is considering a project that will expand its production facilities. The project is expected to produce annual cash flows before tax of $100,000 for the next eight years. The project is considered to be of similar risk to the risk of the firm itself. It will cost PPL $400,000 this year to get this project up and running. The assets will have no value in 8 years' time. Shuting Tia, PPL's manager of finance, has collected current data from the firm's underwriters. Government of Canada 91-day Treasury bills are currently yielding 4.25%. The The expected return on the S&P/TSX Composite Index: forecast to be 10% in the next year New equity capital could be raised by the firm at the current market price, with flotation panta costs of 4.75% of the value of the issue. 37 New bonds could be sold, with flotation costs of 3.67%. The firm faces a corporate tax rate of 40%. The assets belong in an asset class with a CCA rate of 30%. The company will seek to maintain the current capital structure based on existing market value weights. Assume flotation costs are expensed at time = 0. The firm's most recent financial statements are found below: Assets Cash Accounts Receivable. Inventories Total Current Assets Gross Fixed Assets. Accumulated Depreciation Net Fixed Assets TOTAL ASSETS Phillips Pharmaceuticals Limited. Balance Sheet As at December 31, 20XX Liabilities Accruals Accounts Payable 100,000 220,000 450,000 770,000 4,000,000 1,500,000 2,500,000 3,270,000 Total Current Liabilities. Bonds 5.75% Common stock (100,000 outstanding) Retained earnings 30,000 312,000 342.000 1,000,000 1,000,000 928,000 TOTAL LIABILITIES & OWNERS EQUITY 3,270,000

Answer rating: 100% (QA)

1Calculate the Cost of Equity Re R e R f R m R f Where R f is the riskfree rate is the companys beta ... View the full answer